We divided the patients into two groups on the basis of the fold difference in expression of MEG3 in the tumor and the corresponding adjacent normal tissue: MEG3-high group (fold difference >1, n = 22) and MEG3-low group (fold difference <1, n = 58) and then performed a Kaplan–Meier survival analysis and log-rank tests. The gene discussed is MEG3; the disease is neoplasm.